Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention

American Journal of Cardiology

Volumn 110, Issue 1, 2012, Pages 30-35

  Kiviniemi, Tuomas ^a   Karjalainen, Pasi ^b   Pietilä, Mikko ^a   Ylitalo, Antti ^b   Niemelä, Matti ^c   Vikman, Saila ^e   Puurunen, Marja ^f   Biancari, Fausto ^d   Airaksinen, Kari Eino Juhani ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b SATAKUNTA CENTRAL HOSPITAL   (Finland)

^c Division of Cardiology   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; RISK;

ADMINISTRATION, ORAL; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEPARIN; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84862286648     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.02.045     Document Type: Article

References (16)

1. G.Y. Lip, K. Huber, F. Andreotti, H. Arnesen, J.K. Airaksinen, T. Cuisset, P. Kirchhof, F. Marín Consensus Document of European Society of Cardiology Working Group on Thrombosis Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary - a consensus document of the European Society of Cardiology Working Group on thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European association of percutaneous cardiovascular interventions (EAPCI) Eur Heart J 31 2010 1311 1318
2. P.P. Karjalainen, S. Vikman, M. Niemelä, P. Porela, A. Ylitalo, M.A. Vaittinen, M. Puurunen, T.J. Airaksinen, K. Nyman, T. Vahlberg, K.E. Airaksinen Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment Eur Heart J 29 2008 1001 1010
3. E. Jamula, N.S. Lloyd, J.D. Schwalm, K.E. Airaksinen, J.D. Douketis Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: a systematic review and metaanalysis Chest 138 2010 840 847
4. K. Airaksinen, A. Schlitt, A. Rubboli, P. Karjalainen, G. Lip How to manage antithrombotic treatment during percutaneous coronary interventions in patients receiving long-term oral anticoagulation: to "bridge" or not to "bridge"? EuroIntervention 6 2011 520 526
5. K.E. Airaksinen, H. Suurmunne, P. Porela, M. Niemelä, S. Vikman, M. Puurunen, A.P. Annala, F. Biancari, P.P. Karjalainen Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting Am J Cardiol 106 2010 175 179
6. A. Annala, P.P. Karjalainen, F. Biancari, M. Niemelä, A. Ylitalo, S. Vikman, P. Porela, K.E.J. Airaksinen Long-term safety of drug-eluting stents in patients on warfarin treatment Ann Med 2011 [Epub ahead of print]
7. R. Mikkola, J. Wistbacka, J. Gunn, J. Heikkinen, J. Lahtinen, K. Teittinen, K. Kuttila, T. Juvonen, J. Airaksinen, F. Biancari Timing of preoperative aspirin discontinuation and outcome after elective coronary artery bypass graft surgery J Cardiothorac Vasc Anesth 26 2012 245 250
8. K.E. Airaksinen, F. Biancari, P. Karjalainen, R. Mikkola, K. Kuttila, P. Porela, T. Laitio, G.Y. Lip Safety of coronary artery bypass surgery during therapeutic oral anticoagulation Thromb Res 128 2011 435 439
9. A.K. Rao, C. Pratt, A. Berke, A. Jaffe, I. Ockene, T.L. Schreiber, W.R. Bell, G. Knatterud, T.L. Robertson, M.L. Terrin Thrombolysis In Myocardial Infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
10. D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, G.A. van Es, P.G. Steg, M.A. Morel, L. Mauri, P. Vranckx, E. McFadden, A. Lansky, M. Hamon, M.W. Krucoff, P.W. Serruys Academic Research Consortium, on behalf of the Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitionss Circulation 115 2007 2344 2351
11. P.C. Austin Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies Pharm Statist 10 2011 150 161
12. R. Rossini, G. Musumeci, C. Lettieri, M. Molfese, L. Mihalcsik, P. Mantovani, V. Sirbu, T.A. Bass, F. Della Rovere, A. Gavazzi, D.J. Angiolillo Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy Am J Cardiol 102 2008 1618 1623
13. A. Rubboli, W. DeWilde, K. Huber, E. Eechout, I. Herzfeld, J. Valencia, S. Windecker, K.E.J. Airaksinen, G.Y.H. Lip The management of patients on oral anticoagulation undergoing coronary stent implantation: a survey among interventional cardiologists from eight European countries J Interv Cardiol 2011 [Epub ahead of print]
14. R.J. Chang, T.M. Doherty, S.L. Goldberg How does warfarin affect the activated coagulation time? Am Heart J 136 1998 477 479
15. E. Stabile, W. Nammas, L. Salemme, G. Sorropago, A. Cioppa, T. Tesorio, V. Ambrosini, E. Campopiano, G. Popusoi, G. Biondi Zoccai, P. Rubino The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention J Am Coll Cardiol 52 2008 1293 1298
16. J.M. ten Berg, B.A. Hutten, J.C. Kelder, F.W. Verheugt, H.W. Plokker Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications Circulation 103 2001 2042 2047